D-cycloserine: A Novel Treatment for Gulf War Illness (GWDCS)
Status:
Unknown status
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the efficacy of d-cycloserine (DCS) treatment for
Gulf War Illness (GWI). Gulf War veterans with Gulf War Illness experience numerous chronic
health symptoms, including cognition and fatigue, which reduces their quality of life. Gulf
War veterans are in urgent need of novel treatment plans to tackle elusive symptomatology of
Gulf War Illness. By using the literature of previous studies, the investigators have chosen
to investigate d-cycloserine as a possible candidate for treating GWI, specifically cognitive
symptoms. DCS has been shown to reduce neuroinflammation, regulate glutamate levels, and
improve synaptic functioning in key areas of the brain.